



Clinical
Oncology
Society of
Australia

COSA

ATOM

ADVANCED TRAINEE ONCOLOGY MEETING

2018

This meeting is for Medical Oncology Advanced Trainees
Based in ACT, NSW, Queensland, Tasmania and Victoria

• **WHEN**

24 March 2018 9:00am – 6:30pm

• **VENUE**

Mercure Sydney International Airport
22 Levey St, Wolli Creek NSW 2205

• **AGENDA**

Please see over for program highlights
and speaker biographies



ATOM 2018 supported by an
educational/research sponsorship by Roche

- Now in its 11th year COSA is pleased to open registration for ATOM 2018. The Advanced Trainee Oncology Meeting (ATOM) is a unique educational event for Medical Oncology Advanced Trainees with a program developed by trainees.

The ATOM program provides a comprehensive review of current oncology practices and includes presentations on topics not covered in traditional meetings.

COSA thanks Roche for their continued support through educational sponsorship.

REGISTER This is a FREE event.

To register your attendance please complete the online registration form

[CLICK HERE TO REGISTER](#)

Please note attendance is not guaranteed until written confirmation is received from COSA.

TRAVEL

For trainees based in regional NSW, ACT, Queensland, Tasmania and Victoria travel support is available. Please complete the relevant section of the registration form.

REGISTRATION CLOSES (unless the event reaches capacity beforehand):

2 March 2018 (if travel is required)

12 March 2018 (if travel is not required)

If you have any queries regarding this meeting, please contact Fran Doughton via fran.doughton@cancer.org.au or **02 8063 4162**.

PROGRAM

| | | |
|--------------------------|---|------------------------|
| 9.00am > 9.30am | Registration | |
| 9.30am > 9.40am | Welcome | Marie Malica |
| 9.40am > 10.30am | Metastatic breast and triple negative cancer | Belinda Yeo |
| 10.30am > 11.00am | Morning tea | |
| 11.00am > 11.50am | Lung cancer – when to choose what line of therapy | <i>To be confirmed</i> |
| 11.50am > 12.40pm | Radiation therapy for lung cancer | Margot Lehman |
| 12.40pm > 1.40pm | Lunch | |
| 1.40pm > 2.30pm | Clinical trials and statistics in relation to clinical trial design | Martin Stockler |
| 2.30pm > 3.20pm | Management of primary and recurrent ovarian cancer | Michelle Harrison |
| 3.20pm > 3.50pm | Afternoon tea | |
| 3.50pm > 4.40pm | Management of autoimmune toxicities – intricacies of management | Craig Gedye |
| 4.40pm > 5.30pm | Cancer genetics update | Hilda High |
| 5.30pm > 6.30pm | Networking, drinks and canapés | |



CRAIG GEDYE

Dr Craig Gedye BSc(Hons) MBChB FRACP PhD is a physician/scientist, dual trained as a medical oncologist and as a basic science researcher. He looks after patients with melanoma, brain and genitourinary cancers (kidney, prostate, testis, bladder) at the Calvary Mater Newcastle, and translational and basic cancer research at the Hunter Medical Research Institute, University of Newcastle.

He is the Kidney Cancer Subcommittee Chair for ANZUP Cancer Trials Group, and leading clinical trials in cancer immunotherapy. His translational research focus is on cancer complexity and heterogeneity, examining the basis of cellular differentiation in renal cell carcinoma.

MICHELLE HARRISON

Dr Michelle Harrison currently works at Chris O'Brien Lifehouse and Liverpool Hospital specialising in renal, gynaecological, and breast cancers. Following completion of training at Prince of Wales Hospital she underwent fellowships in genetics followed by 2 years overseas where she worked at The Royal Marsden Hospital. She is a member of ANZUP and ANZGOG with a special interest in rare cancers.



HILDA HIGH

Dr Hilda High is a Medical Oncologist who specialises in Cancer Genetics and works in private practice with Sydney Cancer Genetics with rooms in Ultimo and Wahroonga. She provides TeleHealth consults to rural and regional patients throughout Australia. She works closely with the Cancer Institute NSW to develop and maintain genetic testing and risk management protocols for heritable cancer syndromes. Her research interests include cancer prevention and treatment and she has presented her data at national and international conferences. She has a long history of teaching and lecturing and was co-author on the Cancer Council Australia's Clinical Oncology for Students web book.

MARGOT LEHMAN

Dr Margot Lehman obtained her medical degree through the University of Queensland. Following the completion of specialist training in Radiation Oncology, she was accepted into the Radiation Oncology Fellowship program at the University of Toronto and completed a further twelve months of sub-specialty training.

Upon her return to Brisbane, Dr Lehman has sub-specialised in the management of breast, lung and genito-urinary malignancies. She has been actively involved in the implementation of new technologies used to treat these malignancies and has a commitment to ongoing research into these tumour sites.



MARTIN STOCKLER

Martin is Professor of Oncology and Clinical Epidemiology at the University of Sydney, Oncology Co-Director at the NHMRC Clinical Trials Centre, and medical oncologist at the Concord Cancer Centre CRGH and Chris O'Brien Lifehouse RPA. His clinical practice focuses on prostate, bladder, kidney, and testis cancers. His research focuses on using cancer clinical trials to improve survival, quality of life, prognostication, decision-making, and doctor-patient communication.



BELINDA YEO



Dr Belinda Yeo (MBBS, FRACP, MD, BA) is jointly appointed to the Austin Hospital as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer. At the University of Sydney, she completed a Bachelor of Arts Degree in English and Psychology followed by a Bachelor of Medicine and Surgery. She trained at the St Vincent's and Prince of Wales Hospitals in Sydney after which she joined the Breast Unit at The Royal Marsden Hospital, London in 2012 London as a 'Cridlan Clinical and Research Fellow'. In 2014-16 she completed a Research Master's Degree in novel genomic and non-molecular breast cancer risk assays, through The University of London and The Institute of Cancer Research. She became a Fellow of the Royal Australian College of Physicians in 2014. She is a clinical trial investigator and continues her translational research at the ONJ Centre investigating improving personalization and minimising toxicities for patients with breast cancer. She is an Honorary Associate at the School of Cancer Medicine, La Trobe University and a "Choosing Wisely" clinical lead at Austin Health.

REGISTER This is a FREE event.

To register your attendance please complete the online registration form

[CLICK HERE TO REGISTER](#)

Please note attendance is not guaranteed until written confirmation is received from COSA.

REGISTRATION CLOSES (unless the event reaches capacity beforehand):

2 March 2018 (if travel is required)

If you have any queries regarding this meeting, please contact

12 March 2018 (if travel is not required)

Fran Doughton via **fran.doughton@cancer.org.au** or **02 8063 4162**.

• WHEN

24 March 2018
9:00am – 6:30pm

• VENUE

Mercure Sydney International Airport
22 Levey St,
Wolli Creek NSW 2205